Insider · CIK 0001720974

Mahadevia Ankit

Reports to the SEC for 1 company · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001720974

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-08-28	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−6,572 sh	$1.97	−$12.9K	703,294
2025-06-12	SPROSpero Therapeutics, Inc.A Award	Director	AAward	+20K sh	—	—	709,866
2025-02-05	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−14K sh	$0.78	−$10.9K	745,126
2025-02-05	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−55.3K sh	$0.78	−$43.1K	689,866
2024-08-27	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−5,912 sh	$1.35	−$7,981.2	759,085
2024-05-29	SPROSpero Therapeutics, Inc.A Award	Director	AAward	+20K sh	—	—	764,997
2024-02-02	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−63.8K sh	$1.37	−$87.4K	744,997
2023-10-05	SPROSpero Therapeutics, Inc.A Award	Director	AAward	+20K sh	—	—	808,792
2023-08-28	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−9,040 sh	$1.26	−$11.4K	788,792
2023-02-03	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−12.3K sh	$1.81	−$22.2K	797,832
2023-02-01	SPROSpero Therapeutics, Inc.A Award	Director	AAward	+532K sh	—	—	810,118
2022-02-01	SPROSpero Therapeutics, Inc.A Award	Director	AAward	+134K sh	—	—	278,204
2022-02-01	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+188K sh	—	—	187,730
2021-12-27	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+8,000 sh	$5.90	+$47.2K	152,036
2021-12-27	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−8,000 sh	$14.58	−$117K	144,036
2021-12-27	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−8,000 sh	—	—	486,809
2021-08-26	SPROSpero Therapeutics, Inc.A Award	Director	AAward	+78.2K sh	—	—	144,036
2021-02-01	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+179K sh	—	—	179,319
2020-11-04	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+7,370 sh	$5.90	+$43.5K	73,187
2020-11-04	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−7,370 sh	$14.43	−$106K	65,817
2020-11-04	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−7,370 sh	—	—	494,809
2020-11-03	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,137 sh	$5.90	+$12.6K	67,954
2020-11-03	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−2,137 sh	$14.27	−$30.5K	65,817
2020-11-03	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,137 sh	—	—	502,179
2020-10-23	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+20 sh	$5.90	+$118	65,837
2020-10-23	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−20 sh	$14.25	−$285	65,817
2020-10-23	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−20 sh	—	—	504,316
2020-10-14	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+105 sh	$5.90	+$619.5	65,922
2020-10-14	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−105 sh	$14.25	−$1,496.25	65,817
2020-10-14	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−105 sh	—	—	504,336
2020-10-13	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+14.4K sh	$5.90	+$84.8K	80,184
2020-10-13	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−14.4K sh	$14.28	−$205K	65,817
2020-10-13	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−14.4K sh	—	—	504,441
2020-09-08	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+774 sh	$5.90	+$4,566.6	66,591
2020-09-08	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−774 sh	$14.25	−$11K	65,817
2020-09-08	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−774 sh	—	—	518,808
2020-07-09	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,293 sh	$5.90	+$13.5K	68,110
2020-07-09	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−2,293 sh	$14.31	−$32.8K	65,817
2020-07-09	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,293 sh	—	—	519,582
2020-07-07	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+754 sh	$5.90	+$4,448.6	66,571
2020-07-07	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−754 sh	$14.25	−$10.7K	65,817
2020-07-07	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−754 sh	—	—	521,875
2020-06-25	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,642 sh	$5.90	+$15.6K	68,459
2020-06-25	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−2,642 sh	$14.25	−$37.7K	65,817
2020-06-25	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,642 sh	—	—	522,629
2020-06-24	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,880 sh	$5.90	+$22.9K	69,697
2020-06-24	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−3,880 sh	$14.28	−$55.4K	65,817
2020-06-24	SPROSpero Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,880 sh	—	—	525,271
2020-06-23	SPROSpero Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+8,045 sh	$5.90	+$47.5K	73,862
2020-06-23	SPROSpero Therapeutics, Inc.S Sale	Director	SSale	−8,045 sh	$14.33	−$115K	65,817

Recent filings

Accepted (ET)
Sep 34
Mahadevia Ankit0000950170-25-112661
SEC(opens sec.gov)
Jun 164
Mahadevia Ankit0000950170-25-087021
SEC(opens sec.gov)
Feb 54
Mahadevia Ankit0000950170-25-014849
SEC(opens sec.gov)
Aug 294
Mahadevia Ankit0000950170-24-102000
SEC(opens sec.gov)
May 304
Mahadevia Ankit0000950170-24-066625
SEC(opens sec.gov)
Feb 54
Mahadevia Ankit0000950170-24-011496
SEC(opens sec.gov)
Oct 104
Mahadevia Ankit0000950170-23-052692
SEC(opens sec.gov)
Aug 304
Mahadevia Ankit0000950170-23-045442
SEC(opens sec.gov)
Feb 64
Mahadevia Ankit0000899243-23-004039
SEC(opens sec.gov)
Feb 34
Mahadevia Ankit0000899243-23-003939
SEC(opens sec.gov)
Feb 34
Mahadevia Ankit0000899243-22-004591
SEC(opens sec.gov)
Dec 294
Mahadevia Ankit0000899243-21-050049
SEC(opens sec.gov)
Aug 304
Mahadevia Ankit0000899243-21-034502
SEC(opens sec.gov)
Feb 34
Mahadevia Ankit0000899243-21-004783
SEC(opens sec.gov)
Nov 54
Mahadevia Ankit0000899243-20-030490
SEC(opens sec.gov)

Companies

Spero Therapeutics, Inc.DirectorSPRO

Address

C/O SPERO THERAPEUTICS, INC. 675 MASSACHUSETTS AVENUE, 14TH FLOOR

CAMBRIDGE, MA, 02139